Non-adherence to endocrine therapy for breast cancer.

Women with breast cancer often face a variety of decisions regardingtheir treatment at diagnosis and in follow-up. When consideringendocrine therapy, whether for early or advanced breast cancer,there are several options available, with differing side-effectsand routes of administration, from which a woman and her healthcare providers must choose. In this issue of Annals of Oncology,Professor Fallowfield and colleagues elucidate preferences ofwomen with breast cancer regarding endocrine therapy, consideringbetween tablet and injection formulations. Through interviewswith 208 women with a history of early or stable advanced breastcancer, the investigators found that most women (63%) preferredtablet therapy to injections,